Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis
Related Experiment Video
Updated: Feb 8, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Di Zhao1, Hui Liu2, Pingshuan Dong3
1Division of Hypertension, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, 24 Jinghua Avenue, Luoyang, 471003, China. emaildizhao@163.com.
Insights
Azilsartan demonstrated a greater reduction in systolic blood pressure compared to olmesartan in patients with essential hypertension. This meta-analysis highlights azilsartan
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Essential hypertension is a widespread condition requiring effective antihypertensive treatments.
- Azilsartan and olmesartan are both angiotensin II receptor blockers (ARBs) used for hypertension management.
- Previous studies comparing azilsartan and olmesartan have yielded inconsistent results regarding their efficacy.
Purpose of the Study:
- To conduct a meta-analysis comparing the antihypertensive effects of azilsartan versus olmesartan.
- To determine the comparative efficacy of azilsartan and olmesartan in reducing blood pressure in patients with essential hypertension.
Main Methods:
- A systematic literature search was performed across PubMed, Web of Science, and Cochrane Central.
- Included were all published randomized controlled trials comparing azilsartan and olmesartan in essential hypertension patients.
- Data from five trials involving 1402 patients were analyzed.
Main Results:
- Azilsartan showed a statistically significant greater reduction in office systolic blood pressure compared to olmesartan (WMD -2.15 mm Hg, p < 0.01).
- No significant difference was observed in the reduction of office diastolic blood pressure between the two drugs (WMD -0.99 mm Hg, p > 0.05).
- Even at the same dosage, azilsartan demonstrated superior systolic blood pressure reduction (WMD -2.24 mm Hg, p < 0.05), with no significant diastolic difference.
Conclusions:
- This meta-analysis provides evidence that azilsartan is more effective than olmesartan in reducing systolic blood pressure in essential hypertension.
- The findings underscore the importance of well-designed randomized controlled trials for evaluating ARBs in clinical practice.
- Further research may explore long-term outcomes and differential effects of these ARBs.
Objective:
The comparison of antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension has been investigated in several studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension.
Methods:
Pubmed, Web of Science, and Cochrane Central were searched for all published randomized studies comparing the antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension.
Results:
The antihypertensive effects were assessed in 1402 patients included in five trials. The reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan (weighted mean differences (WMD) - 2.15 (95% confidence interval (CI), - 3.78, - 0.53) mm Hg, p < 0.01). There was no significant difference in reduction of office diastolic blood pressure between azilsartan and olmesartan (WMD - 0.99 (95% CI, - 2.06, 0.08) mm Hg, p > 0.05). The reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan at same dose for both drugs (WMD - 2.24 (95% CI, - 4.03, - 0.44) mm Hg, p < 0.05), whereas there was no significant difference in reduction of office diastolic blood pressure between azilsartan and olmesartan (WMD - 0.55 (95% CI, - 1.76, 0.66) mm Hg, p > 0.05).
Conclusions:
This meta-analysis provides the evidence that the reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan in patients with essential hypertension. These findings suggest the importance of strict designed randomized controlled trials in determining antihypertensive effects of angiotensin II receptor blockers in clinical practice.
More Related Videos
Related Concept Videos
Compounds Essential to Human Function
Inorganic Compounds Essential to Human Functioning
Inorganic compounds essential to human functioning include water, salts, acids, and bases. These compounds are inorganic, i.e., they do not have a carbon-hydrogen bond. Water...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Antihypertensive Drugs: Vasodilators
Directing Effect of Substituents: meta-Directing Groups
Antihypertensive Drugs: Action of Diuretics
Hypertension I: Introduction

